WaveMan
WaveMan · Company
BTCY · Biotricity Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BTCY Biotricity (BTCY) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001630113
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Biotricity insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for BIOTRICITY INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Rosa David A
Director
SELL
2021-10-13 SECtraded 2021-10-11
3,318
$10.1K
-99.7%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Oct 8, 2021.
  • The trade is 2.7% of the 125,000 shares held after it.
  • No other insider sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rosa David A sold about $10.1K of BTCY on Oct 11, 2021.
Rosa David A
Director
SELL
2021-10-13 SECtraded 2021-10-08
9,481
$30.3K
-99.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Oct 7, 2021.
  • The trade is 7.4% of the 128,318 shares held after it.
  • No other insider sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rosa David A sold about $30.3K of BTCY on Oct 8, 2021.
Rosa David A
Director
SELL
2021-10-13 SECtraded 2021-10-07
17,228
$53.1K
-99.7%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2021.
  • The trade is 12.5% of the 137,799 shares held after it.
  • No other insider sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rosa David A sold about $53.1K of BTCY on Oct 7, 2021.
Rosa David A
Director
SELL
2021-09-29 SECtraded 2021-09-16
34,977
$120.0K
-99.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 15, 2021.
  • The trade is 22.6% of the 155,027 shares held after it.
  • No other insider sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rosa David A sold about $120.0K of BTCY on Sep 16, 2021, the largest insider sale at the company on our record.
Rosa David A
Director
SELL
2021-09-29 SECtraded 2021-09-15
6,246
$20.4K
-99.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.3% of the 190,004 shares held after it.
  • No other insider sold within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rosa David A sold about $20.4K of BTCY on Sep 15, 2021, the largest insider sale at the company on our record.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+16.0% year over year
more than 64% of Medical Devices
Margin
-15.0% net margin
more than 52% of Medical Devices
Buybacks
no share repurchases reported
Short interest
0.7% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 75% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BTCY

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-91.4%12M
-93%-60%-27%+6%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BTCY: institutional holders (13F)

13F holdings, latest reported quarter
Strengthening Families & Communities, LLC
48,263 sh
$6.0K

Congress trades in BTCY

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BTCY planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

BTCY financials

Revenue growth
+16.0%
XBRL, annual
Net margin
-15.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$16.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-16.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
0.14x
TTM operating cash flow over current debt only, 2025-08-31 (10 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-44.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.7M
market value at close 2026-10-26 on 2026-08-19 shares, plus current debt only, 2025-08-31 (10 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-032025-032024-032023-03
Revenue$16.0M$13.8M$12.1M$9.6M
Gross profit$12.9M$10.6M$8.4M$5.4M
Operating income$1.7M-$2.4M-$8.8M-$15.4M
Net income-$2.4M-$8.4M-$14.1M-$18.7M
EPS (diluted)-0.12-0.56-1.66-2.26
Operating cash flow-$719.0K-$2.4M-$6.7M-$13.5M
Cash$149.8K$365.1K$786.1K$570.5K
SEC XBRL, fiscal years, as known on 2026-10-28

BTCY Stock Sonar score 3/7 axes

Find similar shapesCompare

BTCY ranks highest on risk and compliance (91st percentile) and financial health (65th), and lowest on growth (64th), among Medical Devices peers.

Financial health
65
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt0.14x · 65 pct, sector of 150
Growth
64
Inputs
  • Revenue growth, YoY+16.0% · 64 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
91
Inputs
  • Short interest, % of float+0.7% · 81 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+0.0% · 100 pct, sector of 198
4 not measured: Profitability, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies